ScholarIQanswers from OpenAlex & ORCID
Philip Van Damme
ResearcherPublications, citations & collaboration network
Philip Van Damme is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Philip Van Damme have?
ScholarIQindexed works
Philip Van Damme has 537 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Philip Van Damme have?
ScholarIQcitation count
Philip Van Damme has 30,018 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Philip Van Damme?
ScholarIQh-index
Philip Van Damme has an h-index of 88 in OpenAlex.
What is the i10-index of Philip Van Damme?
ScholarIQi10-index
Philip Van Damme has an i10-index of 311 in OpenAlex.
What is the ORCID of Philip Van Damme?
ScholarIQorcid
The ORCID for Philip Van Damme is on the source record.
What is the OpenAlex record for Philip Van Damme?
ScholarIQopenalex
The OpenAlex for Philip Van Damme is on the source record.
What are the most-cited papers on Philip Van Damme?
ScholarIQmost cited works
EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Peter M. Andersen, Sharon Abrahams, Gian Domenico Borasio, Mamede de Carvalho, Adriano Chiò, Philip Van Damme, Orla Hardiman, Katja Kollewe, Karen Morrison, Susanne Petri, Pierre‐François Pradat, Vincenzo Silani, Barbara Tomik, Maria Wasner, Markus Weber
Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Jonathan Mill, Merit Cudkowicz, Angela Genge, Pamela J. Shaw, Gen Sobue, Robert C. Bucelli, Adriano Chiò, Philip Van Damme, Albert C. Ludolph, Jonathan D. Glass, Jinsy Andrews, Suma Babu, Michael Benatar, Christopher McDermott, Thos Cochrane, Sowmya Chary, Sheena Chew, Han Zhu, Fan Wu, Ivan Nestorov, Danielle Graham, Peng Sun, Manjit McNeill, Laura Fanning, Toby A. Ferguson, Stephanie Fradette
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn, Isabel Illa, Saiju Jacob, John Vissing, Ted M. Burns, John T. Kissel, Srikanth Muppidi, Richard J. Nowak, Fanny O’Brien, Jingjing Wang, Renato Mantegazza, Claudio Mazia, Miguel Wilken, Carolina Ortea, Juliet Saba, Marcelo Rugiero, Mariela Bettini, Gonzalo Vidal, Alejandra Dalila Garcia, Phillipa J. Lamont, Wai-Kuen Leong, Heidi Boterhoven, Beverly Fyfe, L. Jackson Roberts, Mahi Jasinarachchi, Natasha Willlems, Julia Wanschitz, Wolfgang N. Löscher, Jan De Bleecker, Guy Van den Abeele, Kathy de Koning, Katrien De Mey, Rudy Mercelis, Linda Wagemaekers, Délphine Mahieu, Philip Van Damme, Charlotte Smetcoren, Olivier Stevens, Sarah Verjans, Ann D’Hondt, Petra Tilkin, Alzira Alves de Siqueira Carvalho, Rosa Hasan, Igor Dias Brockhausen, David Feder, Daniel Ambrosio, Ana Paula Souto Melo, Rosana Rocha, Bruno Bezerra Rosa, Thabata Veiga, Luiz Augusto da Silva, Jordana Gonçalves Geraldo, Maria da Penha Morita Ananias, Érica Nogueira Coelho, Gabriel Pina Paiva, M Tovar Pozo, Natália Prando, Debora Dada Martineli Torres, Cristiani Fernanda Butinhao, Érica Nogueira Coelho, Luciana Renata Cubas Volpe, Gustavo Duran, Tamires Cristina Gomes da Silva, Luiz Otavio Maia Gonçalves, Lucas Eduardo Pazetto, Luciana Souza Duca, Tomás Augusto Suriane Fialho, Maurício Friedrich, Alexandre Guerreiro, Henrique Mohr, Maurer Pereira Martins, Daiane da Cruz Pacheco, Ana Paula Macagnan, Aline de Cassia Santos, Acary Souza Bullé Oliveira, Ana Carolina Amaral de Andrade, Marcelo Annes, Valéria Cavalcante Lino, Wladimir Bocca Vieira de Rezende Pinto, Carolina Miranda, Fernanda Carrara, Iandra Souza, Angela Genge, Rami Massie, Natasha Campbell, Vera Bril, Hans Katzberg, Mehran Soltani, Eduardo Ng, Zaeem A. Siddiqi, Celile Phan, Derrick Blackmore, Stanislav Voháňka, Josef Bednařík, Magda Chmelikova, Marek Čierny
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Jonathan Mill, Merit Cudkowicz, Pamela J. Shaw, Peter M. Andersen, Nazem Atassi, Robert C. Bucelli, Angela Genge, Jonathan D. Glass, Shafeeq Ladha, Albert Ludolph, Nicholas J. Maragakis, Christopher McDermott, Alan Pestronk, John Ravits, François Salachas, Randall Trudell, Philip Van Damme, Lorne Zinman, C. Frank Bennett, Roger Lane, Alfred Sandrock, Heiko Runz, Danielle Graham, Hani Houshyar, Alexander McCampbell, Ivan Nestorov, Ih Chang, Manjit McNeill, Laura Fanning, Stephanie Fradette, Toby A. Ferguson
Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model
Henk-Jan Westeneng, Thomas P. A. Debray, Anne E Visser, Ruben P. A. van Eijk, James Rooney, Andrea Calvo, Sarah Martin, Christopher McDermott, Alexander G. Thompson, Susana Pinto, Xenia Kobeleva, Angela Rosenbohm, Beatrice Stubendorff, Helma Sommer, Bas Middelkoop, Annelot M. Dekker, Joke J.F.A. van Vugt, Wouter van Rheenen, Alice Vajda, Mark Heverin, Mbombe Kazoka, Hannah Hollinger, Marta Gromicho, Sonja Körner, Thomas Ringer, Annekathrin Rödiger, A. Gunkel, Christopher E. Shaw, Annelien L. Bredenoord, Michael A. van Es, Philippe Corcia, Philippe Couratier, Markus Weber, Julian Großkreutz, Albert C. Ludolph, Susanne Petri, Mamede de Carvalho, Philip Van Damme, Kevin Talbot, Martin R. Turner, Pamela J. Shaw, Ammar Al‐Chalabi, Adriano Chiò, Orla Hardiman, Karel G.M. Moons, Jan H. Veldink, Leonard H. van den Berg